Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 1, 1998, Pages

  Ruffolo Jr , Robert R ^a,b   Feuerstein, Giora Z ^a  

^a SmithKline Beecham Pharmaceutical   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adrenoceptors; Apoptosis; Carvedilol; Congestive heart failure; Oxygen free radicals

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; FREE RADICAL; OXYGEN RADICAL;

APOPTOSIS; CELL DEATH; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFICACY; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; ORGAN BLOOD FLOW; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANTIOXIDANTS; APOPTOSIS; CARBAZOLES; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; PROPANOLAMINES; REACTIVE OXYGEN SPECIES; RECEPTORS, ADRENERGIC, BETA;

EID: 0344447062     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800003-00005     Document Type: Conference Paper

References (48)

1. Cohn JN. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A-30A.
2. Colucci WS. The sympathetic nervous system in congestive heart failure. In: Congestive heart failure. Hosenpund JD, Greenberg, BH, eds. Berlin: Springer-Verlag, 1994:126-35.
3. Krum H, Gu A, Willshire-Clement M, et al. Changes in plasma levels of endothelin reflect the long term clinical and hemodynamic effects of beta-blockade in patients with chronic heart failure (Abstract). J Am Coll Cardiol 1994:172A.
4. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
5. Hershberger RE. β-Adrenergic receptor agonists and antagonists in heart failure. In: Hosepund JD, Greenberg BH, eds. Congestive heart failure, pathophysiology, diagnosis and comprehensive approach to management. Berlin: Springer-Verlag: 1994:454-92.
6. Currie PJ, Kelly MJ, McKenzie A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203-9.
7. McMurray J, Chopra M, Abdullah I, Smith E, Dargie JH. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493-8.
8. Schreck R, Reiber P, Baeccerle PA. Reactive oxygen intermediates as apparently widely used second messengers in the activation of NFκB transcription factor and HIV-1. EMBO J 1991;10:2247-58.
9. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.
10. Mallat L, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in arrhymogenic right ventricular displasia. N Engl J Med 1996;334:1190-6.
11. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
12. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. J Clin Invest 1996; 98:2854-65.
13. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;223:236-41.
14. McMurray J, Abdullah I, Dargie HJ, Shapiro, D. Increased concentrations of tumor necrosis factor in cachectic patients with severe chronic heart failure. Br Heart J 1991;66:356-8.
15. Dutka DP, Elborn JS, Shale DJ, Morris GK. Tumor necrosis factor α in severe congestive heart failure. Br Heart J 1993;70:141-3.
16. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996;92:704-11.
17. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
18. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simulons RL. Negative inotropic effects of cytokine on the heart mediated by nitric oxide. Science 1992;257:337-9.
19. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 1994;90:12-6.
20. Bromme HJ, Holtz J. Apoptosis in the heart: when and why? Mol Cell Biochem 1996;163/164:261-75.
21. Cheng W, Li B, Kajstura J, et al. Stretch induced programmed myocyte cell death. J Clin Invest 1995;96:2247-59.
22. Pinsky DJ, Yang Y, Aji W, et al. Nitric oxide induced apoptosis of adult rat cardiac myocytes. Circulation 1995;92:(suppl 1):565-6.
23. Feuerstein GZ, Ruffolo RR Jr, Yue TL. Apoptosis and congestive heart failure. Trends Cardiovasc Pharmacol 1997;7:249-55.
24. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989;39:327-36.
25. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. The interaction of the enantiomers of carvedilol with alpha-1 and beta-adrenoceptors. Chirality 1989;1:265-70.
26. 2-adrenoceptor subtype: therapeutic implication. Exp Opin Invest Drugs 1997;6:367-87.
27. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38: S82-8.
28. Gellai M, DeWolf R, Ruffolo RR Jr. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology 1990;41:200-6.
29. Ruffolo RR Jr, Boyle DA, Venuti RP, Lukas MA. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993;7:S2-15.
30. Dupont AG, Niepen PVD, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10:130-6.
31. Ruffolo RR Jr, Boyle DA, Brooks DP, et al. Carvedilol, a novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992;10:127-57.
32. Feuerstein GZ, Poste G, Ruffolo RR Jr. Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 1995; 31:307-26.
33. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
34. Yue TL, Liu T, Feuerstein GZ. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992;1:27-35.
35. Ruffolo RR Jr, Boyle D, Venuti RP, Lukas M. Carvedilol (Kredex): a novel multiple action cardiovascular agent. Drugs Today 1991;27:465-92.
36. McPhillips JJ, Schwemer GT, Scott DI, et al. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension Drugs 1988;36(suppl 6):82-91.
37. Kramer JH, Weglicki, WB. A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radical Biol Med 1996;21:813-25.
38. Yue TL, McKenna PJ, Lysko PG, et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994;251:237-43.
39. Feuerstein R, Yue TL. A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994;48:385-91.
40. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotem oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27:532-8.
41. Feuerstein GZ, Shusterman NH, Ruffolo RR Jr. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997;33:453-73.
42. Brunvand H, Froyland L, Hexeberg E, Rynning SE, Berge RK, Grong K. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996;314:99-107b.
43. Brunvand H, Kvitting PM, Rynning SE, Berge RK, Grong K. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol 1996;28:409-17.
44. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in anesthetized minipigs. Cardiovasc Res 1992;26:515-28.
45. Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new beta-adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996;227:128-36.
46. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle ceils. J Pharmacol Exp Ther 1995;273:1442-9.
47. Feuerstein GZ, Yue T-L. Apoptosis and the heart. Basic Appl Myol 1996;6:221-5.
48. Packer MP, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.